Supplementary Figure S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Résumé fourni par la source
Expression biomarker ESR1. (A) Boxplot shows the significant subtype difference of ESR1 expression in uterine leiomyosarcoma tumors (P = 0.00014). (B, C) Kaplan-Meier plots show patients with uterine leiomyosarcoma in CC3 had longer (B) PFS (6.97 months vs. 3.02 months) and (C) OS (21.47 months vs. 10.51 months) than those with uterine leiomyosarcoma not in CC3, although both P values were not significant. (D, E) The survival of patients with uterine leiomyosarcoma was significantly associated with ESR1 mRNA expression status. “High” or “low” ESR1 status was dichotomized by zero after the ESR1 expression values were Z scored. Abbreviation: NA, not available.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Supplementary Figure S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
- Date Crossref
- 03/06/2024
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.